Core B, Tissue Bank provides the infrastructure to transport, receive, process, store, and distribute tissue specimens obtained from patients with myeloproliferative neoplasms (MPN) as well as patients enrolled on clinical trials (Project 4). These specimens are provided to MPN-RC investigators performing translational research for the purpose of developing innovative therapies (Projects1-3) and to the Biomarker & Bioinformatics Core D to perform biomarker analyses to evaluate the effectiveness of specific therapies to deplete MPN hematopoietic stem and progenitor cells (HSC/HPC). Tissues are also available to members of the scientific community at large for translational research. Translational research is dependent on the ready availability of tissues from a sufficient number of accurately diagnosed patients to generate statistically significant data. Because the MPNs are relatively uncommon and their accurate diagnosis can be difficult, there has been a paucity of tissue, linked to clinical data, available to individual investigators at single institutions. Core B fills this void. With an inventory of more than 15000 specimens from more than 1500 individual patients with MPNs, Core B maintains one of the world's largest inventories of MPN tissues available for research. In addition, Core B collects specimens from patients participating in MPN-RC sponsored clinical trials (Project 4) for the purpose of performing biomarker studies to demonstrate the effectiveness of specific therapies on the depletion of MPN hematopoietic stem and progenitor cells (HSC/HPC).
The specific aims of Tissue Bank Core B are to: 1) Receive, process, cryopreserve, and store tissues from MPN patients as well as patients enrolled on clinical trials (Project 4) at MPN-RC clinical sites; 2) Provide a central repository for MPN tissues that are associated with basic data stored in the web-based data bank maintained by Biostatistics and Data Management Core C including clinical, and laboratory data that enable selection and distribution of tissues best suited for each translational research project; 3) Distribute tissues to: MPN Consortium investigators for translational research to develop innovative therapies; MPN Consortium investigators to analyze biomarkers to determine therapeutic and pharmacodynamic response to therapy as well as to predict disease progression; and scientific community at large for translational research. Tissues are available to members of the MPN Research Consortium (MPN-RC) and to the scientific community at large for the performance of translational research. Core B is an essential shared resource that enables translational research that will ultimately lead to the development of molecularly targeted therapies.

Public Health Relevance

MPN-RC investigators are performing translational research in order to develop treatments and cures for myeloproliferative neoplasms (MPN) which are blood cancers. This research requires tissue specimens from patients with these diseases. MPN patients donate blood, bone marrow and spleen tissue to be used for research. The tissues are shipped to Core B Tissue Bank where they are processed, stored and then distributed to scientists for research purposes.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
New York
United States
Zip Code
Gilles, Laure; Arslan, Ahmet Dirim; Marinaccio, Christian et al. (2017) Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest 127:1316-1320
Varricchio, Lilian; Falchi, Mario; Dall'Ora, Massimiliano et al. (2017) Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function. Front Cell Dev Biol 5:96
Zingariello, M; Sancillo, L; Martelli, F et al. (2017) The thrombopoietin/MPL axis is activated in the Gata1(low) mouse model of myelofibrosis and is associated with a defective RPS14 signature. Blood Cancer J 7:e572
Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2017) The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp Hematol 50:53-76
Lanikova, Lucie; Reading, N Scott; Hu, Hao et al. (2017) Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer. Oncotarget 8:11739-11747
Sergueeva, Adelina; Miasnikova, Galina; Shah, Binal N et al. (2017) Prospective study of thrombosis and thrombospondin-1 expression in Chuvash polycythemia. Haematologica 102:e166-e169
Wang, Linghua; Wheeler, David A; Prchal, Josef T (2016) Acquired uniparental disomy of chromosome 9p in hematologic malignancies. Exp Hematol 44:644-52
Klionsky, Daniel J (see original citation for additional authors) (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222
Migliaccio, Anna Rita (2016) To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation. Exp Hematol 44:706-12
Spangrude, Gerald J; Lewandowski, Daniel; Martelli, Fabrizio et al. (2016) P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells 34:67-82

Showing the most recent 10 out of 181 publications